Search details
1.
Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases.
Breast Cancer Res Treat
; 193(3): 613-623, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35460498
2.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat
; 190(2): 265-275, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34476645
3.
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
Breast Cancer Res
; 22(1): 121, 2020 11 04.
Article
in English
| MEDLINE | ID: mdl-33148288
4.
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Breast Cancer Res
; 22(1): 48, 2020 05 15.
Article
in English
| MEDLINE | ID: mdl-32414394
5.
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 52, 2020 05 20.
Article
in English
| MEDLINE | ID: mdl-32434589
6.
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 4, 2020 01 10.
Article
in English
| MEDLINE | ID: mdl-31924241
7.
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Breast Cancer Res Treat
; 181(3): 623-633, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32378051
8.
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Nature
; 508(7494): 103-107, 2014 Apr 03.
Article
in English
| MEDLINE | ID: mdl-24670641
9.
Metastatic triple-negative breast cancer: Established and emerging treatments.
Breast J
; 26(9): 1793-1796, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32578306
10.
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Breast Cancer Res
; 21(1): 100, 2019 09 02.
Article
in English
| MEDLINE | ID: mdl-31477168
11.
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
Breast Cancer Res Treat
; 178(2): 251-261, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31388936
12.
Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ß-catenin and TGFß signaling pathways.
Eur J Nutr
; 58(8): 3207-3219, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-30460610
13.
The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast.
Breast J
; 25(6): 1171-1176, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31321854
14.
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Breast Cancer Res
; 20(1): 108, 2018 09 05.
Article
in English
| MEDLINE | ID: mdl-30185216
15.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Cancer Res Treat
; 167(3): 731-740, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29110152
16.
Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
J Biol Chem
; 291(45): 23756-23768, 2016 Nov 04.
Article
in English
| MEDLINE | ID: mdl-27650498
17.
Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.
Cancer
; 123(1): 114-121, 2017 Jan 01.
Article
in English
| MEDLINE | ID: mdl-27571243
18.
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Mol Cell Proteomics
; 14(7): 1959-76, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25953087
19.
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling.
Proc Natl Acad Sci U S A
; 111(24): 8838-43, 2014 Jun 17.
Article
in English
| MEDLINE | ID: mdl-24876273
20.
Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases.
J Biol Chem
; 295(27): 9266, 2020 Jul 03.
Article
in English
| MEDLINE | ID: mdl-32620694